Showing 5051-5060 of 8729 results for "".
- Mohs Surgery as Effective as Wide Excision for Lentigo Maligna Melanoma: Studyhttps://practicaldermatology.com/news/mohs-surgery-effective-wide-excision-lentigo-maligna-melanoma-study/2468603/New research suggests Mohs micrographic surgery (MMS) may be as effective as wide local excision (WLE) in treating lentigo maligna (LM) and lentigo maligna melanoma (LMM), without compromising melanoma-specific survival rates. Lentigo maligna, often found on sun-damaged skin in older patie
- Botanix Announces Expanded Payer Coverage for Sofdrahttps://practicaldermatology.com/news/botanix-announces-expanded-payer-coverage-sofdra/2468602/Botanix announced today that Ascent Health, second largest Payer (insurer) organization in the US, will now cover Sofdra™ (sofpironium) topical gel, 12.45%, for the treatment of primary axillary hyperhydrosis. According to a press release from Botanix, Ascent represents approximat
- Roflumilast Cream 0.15% Receives Glamour's Best Eczema Product Award for 2024https://practicaldermatology.com/news/roflumilast-cream-015-receives-glamours-best-eczema-product-award-2024/2468585/Arcutis Biotherapeutics announced today that ZORYVE® (roflumilast) cream 0.15% has been named Best Eczema Product by Glamour magazine in its 2024 Health and Wellness Awards. The cream, which is the first once-daily FDA-approved topical treatment specifically indicated for mild to
- Study: PLLA-SCA Induces Adipogenesis and Volumization of the Hip Dellhttps://practicaldermatology.com/news/study-plla-sca-induces-adipogenesis-and-volumization-hip-dell/2468575/Injecting poly-l-lactic acid (PLLA-SCA) is a safe and effective method for durable volumization and aesthetic improvement of the hip dell, and may promote adipogenesis and elastogenesis, according to a new study published in Dermatologic Surgery. “People have used Sculptra for years, but w
- Vichy Dercos Launches Advanced Scalp Line in US Markethttps://practicaldermatology.com/news/vichy-dercos-launches-advanced-scalp-solutions-us-market/2468512/Vichy Decros has announced the US launch of its new three-step system targeting scalp concerns, representing w
- AD Drugs Market Predicted to Grow From $10.5 Billion to $24.5 Billionhttps://practicaldermatology.com/news/ad-drugs-market-predicted-grow-105-billion-245-billion/2468511/A new market research report predicts that the global atopic dermatitis (AD) drugs market will grow at a compound annual growth rate of 9.1% from now through 2033, going from $10.5 billion in 2023 to $24.5 billion by 2033. The report, from market.us, is titled, “Atopic Dermatitis Drugs Mar
- ImmunoSkin Conference Explores Inflammatory Skin Conditionshttps://practicaldermatology.com/news/immunoskin-conference-explores-inflammatory-skin-conditions/2468494/The third annual ImmunoSkin conference was held October 26-27 in Barcelona, Spain, highlighting new therapeutic strategies and facilitating exchange about the biological mechanisms of psoriasis and atopic dermatitis through clinical case studies and expert debates. The event was hosted by
- ECZTEND: Tralokinumab-ldrm Achieves Lasting Efficacy in AD Patientshttps://practicaldermatology.com/news/ecztend-tralokinumab-ldrm-achieves-lasting-efficacy-ad-patients/2468493/Final results presented at Fall Clinical 2024 from the ECZTEND study confirmed long-term safety and efficacy of tralokinumab-ldrm in adolescents and adults with moderate-to-severe atopic dermatitis (AD). The open-label, single-arm trial included 1,672 participants who transitioned from nin
- Deuruxolitinib Shows Efficacy in Adults with Severe Alopecia Areatahttps://practicaldermatology.com/news/deuruxolitinib-shows-efficacy-adults-severe-alopecia-areata/2468485/New findings on LEQSELVI™ (deuruxolitinib) presented at the 44th Annual Fall Clinical Dermatology Conference showed sustained efficacy and safety in adults with severe alopecia areata (AA). According to a press release from the manufacturer, the FDA-approved JAK inhibitor showed meaningfu
- Promising Pipeline for CSU Optionshttps://practicaldermatology.com/news/promising-pipeline-csu-options/2468488/Cleveland Clinic allergist Dr. David Lang joined Dr. Dawn Merritt and Dr. Brad P. Glick to discuss chronic spontaneous urticaria (CSU) at the 44th Annual Fall Clinical Dermatology Conference and noted that the future is very promising. “Our recent understanding of chronic urticaria has imp